Toronto, Ontario--(Newsfile Corp. - August 31, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") today announced its financial results for the three and nine-month periods ended June 30, 2026 ("Q3 Fiscal 2026"). The Company's condensed interim consolidated financial statements and related management's discussion and analysis for the period (collectively, the "Interim Filings") have been filed under the Company's profile on SEDAR+ at www.sedarplus.ca. All dollar amounts in this news release are expressed in Canadian dollars unless otherwise indicated.
Q3 Fiscal 2026 Highlights:
First commercial revenue: nine-month revenue of $112,000, up from $15,551 in the prior comparative period, as distribution and commercialization initiatives put in place over the past year began converting into recurring commercial activity for the first time in the Company's history.
Expanding distribution network: continued NIRLAB SA ("NIRLAB") device sales, expanded partnerships with Indigenous and First Nations communities, and a planned relaunch of the Drug Lab 118 Ltd. rapid detection strip portfolio.
Completed rebrand and cross-border uplisting: shares now trade as Altrova Health Inc. on the CSE (ROVA) and OTCQB (ATVHF), aligning the Company's US and Canadian trading identity with its healthcare platform.
Lower discretionary costs: general and administrative, investor relations and professional fees each declined year-over-year even as the Company scaled its commercial operations.
Management Commentary
"This quarter marks an important turning point for Altrova," said Geoff Benic, Chief Executive Officer of Altrova Health. "Generating our first meaningful product revenue tells us that the distribution relationships and commercial partnerships we have built over the past year are starting to convert into real activity. Combined with a refreshed board and leadership team, we believe we are building the foundation to carry that momentum forward."
"This quarter reflects the direction the board wants to see from this management team," said The Hon. Tony Clement, Chairman of the Board of Altrova Health. "The Company is beginning to show real commercial progress, and it's doing so with the financial discipline and leadership strength this stage of growth requires. The board's role now is to keep holding management to that standard."
Financial Summary
Selected results for the nine-month period ended June 30, 2026, compared to the nine-month period ended June 30, 2025:
| Results of Operations |
| Nine Months Ended June
30, 2026 |
|
| Nine Months Ended June
30, 2025 |
|
| Revenue | $ | 112,000 |
| $ | 15,551 |
|
| Gross Profit | $ | 62,488 |
| $ | 9,702 |
|
| Gross Margin |
| 55.8% |
|
| 62.4% |
|
| Net loss and comprehensive loss | $ | (2,351,996 | ) | $ | (1,098,177 | ) |
Altrova's third fiscal quarter results reflect a company translating a year of distribution and commercialization work into measurable commercial output for the first time. Revenue grew to $112,000 for the nine-month period, as sales through the Company's NIRLAB channels moved from occasional transactions toward a more consistent flow of commercial activity. Gross profit followed the same trajectory, rising to $62,488, providing evidence that the growth in revenue is carrying through to the product level, and not simply widening the top line. Gross margin moderated to 55.8% from 62.4%, consistent with the shift from a small number of early-stage transactions in the prior comparative period to broader-based commercial sales in the current year.
Net loss and comprehensive loss increased to $2,351,996 from $1,098,177. More than 60% of that increase is attributable to two non-cash items rather than the Company's core operating costs: a $330,640 one-time charge recognized upon the mutual termination of an exclusive license agreement in May 2026, representing the write-off of that license's remaining carrying value, not a cash expenditure, and a $463,785 increase in non-cash share-based compensation tied to stock option vesting. The remainder of the increase reflects higher management and consulting fees supporting the Company's expanded operating platform, partially offset by lower general and administrative, investor relations and professional fees, indicating that the Company's core cash operating costs remained disciplined even as commercial activity scaled."
About Altrova Health Inc.
Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) is a Canadian public company building a growing portfolio of health solutions across detection, protection, treatment, and wellness. The Company's current product portfolio includes exclusive Canadian distribution rights for the NIRLAB SA ("NIRLAB") NIRLIGHT drug analysis device, the ToxiShield fentanyl and drink-spiking detection product line, and the O-Spray product line, alongside the rapid detection strip portfolio of its subsidiary Drug Lab 118 Ltd.
For more information, please visit: www.altrovahealth.com.
On behalf of the Board of Directors of Altrova Health Inc.
"Geoff Benic"
Geoff Benic, CEO
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. Forward-looking statements in this news release include, but are not limited to, statements regarding: the Company's expectations for the continued growth of its commercial and distribution network, including NIRLAB device sales and the planned relaunch of the Drug Lab 118 rapid detection strip portfolio; management's and the board's expectations regarding the Company's ability to convert its distribution and commercial relationships into recurring revenue; the Company's ability to build on the operational momentum described in this news release; and the Company's future growth, profitability and business prospects generally.
Forward-looking statements are based on a number of estimates and assumptions that, while considered reasonable by management as of the date of this news release, are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These factors include, among others: the Company's limited operating history and history of losses; uncertainty as to whether the Company will continue to generate revenue or achieve profitability; the Company's ability to continue as a going concern, as described in the Interim Filings; the Company's dependence on additional equity or debt financing to fund its operations, which may not be available on acceptable terms or at all; risks associated with the commercialization of new products and technologies, including market acceptance and competition; the Company's reliance on third-party distribution, licensing and supply relationships; regulatory risks applicable to the Company's products in the jurisdictions in which it operates; and general economic, market and industry conditions.
Additional risks and uncertainties are described in the Company's continuous disclosure filings available under its profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date hereof, and the Company undertakes no obligation to update or revise them, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312309
© 2026 Canjex Publishing Ltd. All rights reserved.